Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

245
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
245
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

17.5K
Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human...
17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

40.5K
In this article, we examine the methodology and considerations relevant to the FDA approved depression treatment protocol using the Neuronetics NeuroStar TMS...
40.5K
Isolation and Derivation of Mouse Embryonic Germinal Cells14:01

Isolation and Derivation of Mouse Embryonic Germinal Cells

16.6K
The ability of embryonic germinal cells to differentiate into primordial germinal cells during early development stages is a perfect model to address our hypothesis about cancer and infertility. This protocol shows how to isolate primordial germinal cells from developing gonads in 10.5-11.5 days post coitum mouse...
16.6K
Obedience01:08

Obedience

35.2K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.2K
Ethics in Research01:56

Ethics in Research

25.4K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tradipitant: First Approval.

Drugs·2026
Same author

Depemokimab: First Approval.

Drugs·2026
Same author

Sibeprenlimab: First Approval.

Drugs·2026
Same author

Rilzabrutinib: First Approval.

Drugs·2025
Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025
Same author

Paltusotine: First Approval.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

FDA Approved Drugs: Changes to Approved Drugs
01:26

FDA Approved Drugs: Changes to Approved Drugs

Published on: October 3, 2025

245

Zongertinib: First Approval.

Arnold Lee1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.

Drugs
|January 18, 2026
PubMed
Summary
This summary is machine-generated.

Zongertinib is a new HER2-specific inhibitor approved for HER2-mutant non-small cell lung cancer (NSCLC). This milestone follows positive results from the Beamion LUNG-1 trial, offering a new treatment option for advanced NSCLC patients.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

Related Experiment Videos

Last Updated: Jan 20, 2026

FDA Approved Drugs: Changes to Approved Drugs
01:26

FDA Approved Drugs: Changes to Approved Drugs

Published on: October 3, 2025

245
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.5K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Zongertinib (HERNEXEOS®) is an irreversible, HER2-specific tyrosine kinase inhibitor.
  • It targets advanced solid tumors with HER2 aberrations, including HER2 mutations.
  • It spares cells with wild-type EGFR, enhancing selectivity.

Purpose of the Study:

  • To summarize the development milestones of zongertinib.
  • To highlight its first accelerated approval in the USA for NSCLC.

Main Methods:

  • Phase Ia/Ib Beamion LUNG-1 trial.
  • Investigated zongertinib in patients with previously treated HER2-mutant NSCLC.

Main Results:

  • Positive results from the Beamion LUNG-1 trial led to accelerated approval.
  • Zongertinib demonstrated efficacy in HER2-mutant NSCLC.

Conclusions:

  • Zongertinib received accelerated approval in August 2025 in the USA.
  • It is indicated for adult patients with unresectable or metastatic NSCLC with specific HER2 mutations and prior therapy.